Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Breast Cancer Vaccine Shows Promise in Small Clinical Trial

December 1, 2014 1:02 pm | by Julia Evangelou Strait, Washington University | News | Comments

A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients’ immune systems to attack tumor cells and helped slow the cancer’s progression. The study appears in Clinical Cancer Research. Read more...


HIV Drug Blocks Bone Metastases in Prostate Cancer

December 1, 2014 12:55 pm | by Thomas Jefferson University | News | Comments

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online in the journal Cancer Research, researchers show that the receptor CCR5 best known for its role in HIV therapy, may also be involved in driving the spread of prostate cancer to the bone. Read more...


Imaging Shows Brain Connection Breakdown in Early Alzheimer’s

December 1, 2014 12:45 pm | News | Comments

Changes in brain connections visible on MRI could represent an imaging biomarker of Alzheimer's disease, according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA). Read more...


Study Points to New Therapeutic Strategy in CKD

December 1, 2014 12:37 pm | by UPenn | News | Comments

The few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy. Read more...


Actinium 's AML Drug Receives Orphan-Drug Designation

December 1, 2014 12:23 pm | News | Comments

Actinium announced that the FDA has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial. Read more...


Abivax Completes First-In-Man Study of HIV Treatment

December 1, 2014 10:55 am | News | Comments

Abivax, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV. Read more...


Mylan, Gilead to Enhance Access to TAF-based HIV Treatments in Developing Countries

December 1, 2014 9:38 am | News | Comments

Mylan Inc. announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.  Read more...


Who Will Miss Ebola Targets Set for Dec 1?

December 1, 2014 9:26 am | by Maria Cheng, AP Medical Writer - Associated Press | News | Comments

Two months ago, the World Health Organization launched an ambitious plan to stop the deadly Ebola outbreak in West Africa, aiming to isolate 70% of the sick and safely bury 70% of the victims in the three hardest-hit countries - Guinea, Liberia and Sierra Leone - by December 1. Read more...


Eli Lilly, AstraZeneca Launch Patient Trial for Alzheimer's Treatment

December 1, 2014 9:17 am | News | Comments

Eli Lilly and Company and AstraZeneca announced enrollment of the first patient into Amaranth, a Phase 2/3 study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. Read more...


Novartis's Gilenya Fails to Treat Difficult Form of MS

December 1, 2014 9:04 am | News | Comments

Novartis announced that the Phase 3 INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures. The safety results were consistent with the well-characterized safety profile of fingolimod in relapsing MS (RMS). Read more...


Cloning Pioneer Proposes Global Network of IPS Cell Banks

November 28, 2014 9:55 am | by Cynthia Fox, Science Editor | Articles | Comments

Ian Wilmut, father of the cloned Dolly the Sheep, is now proposing to father a global induced pluripotent stem (iPS) cell handbook— to go with a proposed new global network of iPS cell haplobanks. Read more...                                   


Big Data to Make Big Difference in Childhood Cancer Treatment

November 26, 2014 12:00 pm | News | Comments

Research crunching vast amounts of data on childhood cancer to better tailor treatment is one step closer to assisting clinicians through a collaboration that boasts a virtual pipeline that visualizes large quantities of patient data to help hospital clinicians better diagnose and treat childhood cancer patients.


Chinese-Built Ebola Center Dedicated in Liberia

November 26, 2014 12:00 pm | by Jonathan Paye-Layleh and Clarence Roy-Macaulay, Associated Press | News | Comments

China, one of the first countries to send aid to battle Ebola in West Africa, ramped up the assistance significantly Tuesday by opening a 100-bed treatment center in Liberia as rows of uniformed Chinese army medics stood at attention.      


First-in-Human Study of Antibody for AML Kicks Off

November 26, 2014 12:00 pm | News | Comments

Oxford BioTherapeutics and Berlin Chemie/Menarini Biotech/Menarini Ricerche announced that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). Read more...


A Hybrid Vehicle That Delivers DNA

November 26, 2014 12:00 pm | News | Comments

A new hybrid vehicle is under development. Its performance isn’t measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.